Novartis v. Nanjing Noratech: Consent Judgment in Sacubitril-Valsartan Heart Failure Patent Dispute
Novartis AG brought a patent infringement action in Delaware against Chinese generic manufacturer Nanjing Noratech Pharmaceutical over two patents protecting sacubitril-valsartan dosage regimens for heart failure. After 799 days of litigation, the parties resolved the dispute through a consent judgment signed by Judge Richard G. Andrews on June 17, 2025.
Novartis locks in court-entered IP protection on Entresto dosage patents
Novartis AG filed Case No. 1:23-cv-00401 in the District of Delaware on April 10, 2023, asserting infringement of US8101659B2 and US11058667B2 against Nanjing Noratech Pharmaceutical Co., Ltd., a Chinese generic drug manufacturer. The patents at issue protect pharmaceutical compositions and dosage regimens for sacubitril-valsartan — the active combination sold commercially as Entresto — in the treatment of heart failure. The case was assigned to Judge Richard G. Andrews and consolidated within the broader Entresto multidistrict litigation (1:20-md-02930-RGA).
The case concluded on June 17, 2025, via a consent judgment entered between Novartis Pharmaceuticals Corporation, Gerbera Therapeutics Inc., and Nanjing Noratech Pharmaceutical Co. A consent judgment is a court-entered order reflecting agreed terms — it carries full judicial force and is enforceable as a court order, unlike a private settlement agreement. For Novartis, this outcome typically signals that the defendant has agreed to be bound by specific restrictions, most commonly an acknowledgment of patent validity or enforceability and a bar on launching a generic product before a negotiated date.
At 799 days, this case ran substantially longer than many comparable ANDA-linked pharmaceutical patent disputes resolved before trial, suggesting the parties engaged in meaningful discovery and potentially substantive claim construction or validity briefing before reaching agreed terms. The specific commercial conditions of the consent judgment — including any agreed entry date for Nanjing Noratech’s product — are not publicly disclosed. The involvement of Gerbera Therapeutics Inc. as a named party in the judgment, despite not appearing as a plaintiff in the original complaint, is consistent with Novartis’s licensing and commercialization structure and warrants attention from competitors mapping the Entresto patent estate.
Filing to Consent Judgment in 799 days
799 days — longer than the typical ANDA first-instance resolution of ~400–600 days
Consent judgment entered: what this resolution means for both parties
Consent judgment is a court order, not merely a private deal
A consent judgment differs materially from a private settlement. Signed by Judge Andrews and entered on the docket, it is enforceable as a judicial order. Violation by Nanjing Noratech — for example, launching a generic sacubitril-valsartan product in breach of agreed terms — could expose the defendant to contempt proceedings, not merely breach-of-contract claims. This gives Novartis a significantly stronger enforcement tool than a confidential term sheet.
Judicially enforceableNovartis secures binding protection for Entresto dosage patents
For Novartis, a consent judgment in an infringement action typically signals that the defendant has acknowledged — at minimum in practical effect — that launching its product would infringe the asserted patents. US8101659B2 and US11058667B2 now carry the weight of a court order behind them against this specific defendant. This strengthens Novartis’s negotiating posture in parallel proceedings against other generic challengers within the same multidistrict litigation.
Patents upheld in effectNanjing Noratech’s U.S. launch timeline subject to agreed constraints
By consenting to judgment, Nanjing Noratech avoids the risk and cost of a full trial but accepts binding court-ordered restrictions on its U.S. market entry for sacubitril-valsartan. The specific entry date, if any, is not publicly disclosed. The company retains the ability to commercialize once any agreed exclusivity window expires, but the consent judgment forecloses further litigation of the specific claims resolved — a significant constraint for this product line.
Launch date constrainedEntresto generic landscape narrows further for remaining challengers
Nanjing Noratech’s consent judgment removes one active ANDA challenger from the Entresto generic competitive front, at least temporarily. Other generic manufacturers watching this proceeding within the MDL will note that Novartis has now secured court-entered orders against multiple defendants. The inclusion of Gerbera Therapeutics in the judgment suggests Novartis’s IP enforcement extends through its licensing structure — competitors should map all related entities before asserting design-around freedom.
Generic competition delayedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Novartis, AG | Company | Global pharmaceutical innovator — holder of US8101659B2 and US11058667B2 covering sacubitril-valsartanSearch in Eureka ↗ |
| Defendant | Nanjing Noratech Pharmaceutical Co., Ltd. | Company | Chinese generic pharmaceutical manufacturer seeking U.S. market entry for sacubitril-valsartan combination therapySearch in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Christina Schwarz | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Christopher E. Loh | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Daniel A. O’Brien | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Deanne E. Maynard | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Erin Belfield | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Jared L. Stringham | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Melinda R. Roberts | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Nicholas N. Kallas | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Shannon K. Clark | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff law firm | McCarter & English, LLP | Law Firm | Representing Novartis, AGSearch in Eureka ↗ |
| Plaintiff law firm | Venable LLP | Law Firm | Representing Novartis, AGSearch in Eureka ↗ |
| Defendant counsel | Avery Hitchcock | Attorney | Counsel for Nanjing Noratech Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Defendant counsel | Denise Seastone Kraft | Attorney | Counsel for Nanjing Noratech Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Defendant counsel | Dominick T. Gattuso | Attorney | Counsel for Nanjing Noratech Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Defendant counsel | Don J. Mizerk | Attorney | Counsel for Nanjing Noratech Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Defendant counsel | Matthew M. Kamps | Attorney | Counsel for Nanjing Noratech Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Defendant counsel | Thomas P. Heneghan | Attorney | Counsel for Nanjing Noratech Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Defendant law firm | Heyman Enerio Gattuso & Hirzel, LLP | Law Firm | Representing Nanjing Noratech Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Presiding judge | Judge Richard G. Andrews | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consent judgment was entered between Novartis Pharmaceuticals Corporation, Gerbera Therapeutics Inc., and Nanjing Noratech Pharmaceutical Co. — a trilateral structure that reflects Novartis’s multi-entity IP enforcement architecture. The inclusion of Gerbera Therapeutics suggests rights to the asserted patents flow through a licensing arrangement. As a court-entered order, the judgment is binding and judicially enforceable against Nanjing Noratech, carrying materially greater enforcement weight than a private settlement. The agreed terms — including any future launch date — are not publicly disclosed, which is typical for consent judgments in ANDA-linked pharmaceutical patent disputes.
US8101659B2 & US11058667B2 — Sacubitril-Valsartan Heart Failure Treatment Patents
US8101659B2 (application no. US12/147570) covers methods of treatment and pharmaceutical compositions related to the sacubitril-valsartan combination — the active ingredient pairing at the core of Novartis’s Entresto franchise. US11058667B2 (application no. US15/572399) extends protection to specific dosage regimens for administering sacubitril-valsartan in heart failure treatment. Together, these patents represent a layered exclusivity strategy: one protecting the compound or composition, the other protecting how it is clinically deployed — a structure that forces generic challengers to clear both barriers independently.
The sacubitril-valsartan patent estate is among the most commercially significant in cardiovascular pharmacology. Entresto generated multi-billion dollar annual revenues for Novartis, making the Entresto patent portfolio a high-priority enforcement target and a correspondingly high-priority challenge target for generic manufacturers worldwide. US11058667B2’s dosage regimen claims are particularly significant: even a generic manufacturer that successfully designs around or invalidates the composition claims of US8101659B2 may still face infringement exposure under the method-of-use claims. This layered structure is a deliberate and increasingly common innovation protection strategy in the pharmaceutical sector.
Should your team run an FTO against US8101659B2 and US11058667B2?
Any company developing, manufacturing, or commercializing a sacubitril-valsartan combination product — or any angiotensin receptor-neprilysin inhibitor (ARNI) therapy — should treat these two patents as mandatory FTO targets. The consent judgment against Nanjing Noratech confirms that Novartis is actively enforcing both patents in U.S. federal court, and the MDL structure means enforcement actions against additional ANDA filers are already in progress. R&D and regulatory teams planning U.S. NDA or ANDA submissions for ARNI-class heart failure therapies should assess both composition and dosage regimen claim scope before advancing clinical or regulatory programs.
PatSnap Eureka’s FTO Search Agent enables your IP and R&D teams to map the full claim scope of US8101659B2 and US11058667B2, identify all continuation, divisional, and related family members, and surface prior art relevant to validity challenges — in a fraction of the time required by manual prosecution history review. Eureka can also monitor the Entresto MDL docket for new consent judgments or trial outcomes affecting the remaining generic challenger landscape, giving your team continuous competitive intelligence on one of cardiovascular pharma’s most contested patent estates.
Run a freedom-to-operate analysis on US8101659B2 to assess your product’s exposure
Run FTO in Eureka →Similar Pharma Patent Infringement Cases in Delaware District Court
Cases involving ANDA-linked sacubitril-valsartan or ARNI heart failure patent enforcement in the Delaware District Court and related MDL proceedings.
What this case signals for the pharmaceutical patent enforcement landscape
The Nanjing Noratech consent judgment reinforces Novartis’s multifront IP enforcement strategy around Entresto’s sacubitril-valsartan patent estate.
Consent judgments in pharma MDLs signal coordinated enforcement pressure
When an innovator secures consent judgments across multiple defendants in an MDL, it signals that the asserted patents are sufficiently strong to push challengers to negotiate rather than litigate to verdict. Competitors and remaining generic filers in the Entresto MDL should assess their validity positions carefully before proceeding to trial.
Gerbera Therapeutics’ inclusion signals licensing entity matters for FTO
The appearance of Gerbera Therapeutics Inc. as a named party in the consent judgment — despite not being the original plaintiff — is consistent with Novartis structuring rights through licensing entities. Any freedom-to-operate analysis on sacubitril-valsartan must account for this entity’s role in the enforceability chain, not just Novartis AG itself.
Novartis v Nanjing — key questions answered
The consent judgment, entered June 17, 2025, resolved Novartis’s infringement action over US8101659B2 and US11058667B2 covering sacubitril-valsartan. It is a court-entered order binding on Nanjing Noratech and Gerbera Therapeutics Inc. The specific commercial terms, including any agreed generic launch date, are not publicly disclosed in the court record.
Novartis asserted US8101659B2, covering methods of treatment and pharmaceutical compositions for sacubitril-valsartan, and US11058667B2, covering sacubitril-valsartan dosage regimens for heart failure treatment. Both patents relate to Novartis’s Entresto product and were asserted in the context of the broader Entresto multidistrict litigation in Delaware.
Gerbera Therapeutics Inc. appears as a named party in the consent judgment despite not being listed as a plaintiff in the original complaint. This is consistent with Novartis structuring patent rights through licensing entities. Gerbera Therapeutics’ inclusion suggests it holds or co-holds rights relevant to the asserted patents, and any FTO or challenge strategy must account for this entity’s standing.
The consent judgment does not directly bind other defendants in the Entresto MDL (1:20-md-02930-RGA), but it signals that Novartis has secured court-entered orders against at least one Chinese generic manufacturer. Remaining generic challengers should note that Novartis is willing and able to pursue enforcement to the point of consent judgment, suggesting the asserted patents withstood meaningful adversarial review before resolution.
A consent judgment is entered by the court as a judicial order, carrying full contempt-of-court enforcement power if violated. A private settlement is a contract between parties enforceable only through breach-of-contract proceedings. In the pharmaceutical patent context, consent judgments typically include explicit restrictions on generic launch timing and are preferable to Novartis because they are harder for defendants to circumvent unilaterally.
PatSnap Eureka searches patents and litigation data to answer instantly.